|
GENZYME REPORTS PHASE III DATA SHOWING CAMPATH IS SUPERIOR TO CHLORAMBUCIL AS A FIRST-LINE THERAPY IN B-CLL
16 April 2007 - BTG
| BTG plc, the medical innovations company, notes that its licensee Genzyme Corporation has published positive results from a Phase III study comparing Campath with Chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukaemia. An extract from the announcement follows. |
BTG plc, the medical innovations company, notes that its licensee Genzyme Corporation has published positive results from a Phase III study comparing Campath with Chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukaemia. An extract from the announcement follows.
http://www.btgplc.com
About: BTG
BTG is an intellectual property and technology commercialisation company that operates internationally. BTG creates value by investing in intellectual property and technology development, and in early stage ventures. We realise value through technology licensing, patent assertion and sale of equity investments. Through a multidisciplinary approach, we apply intellectual property and commercial expertise, together with specialist skills in science and technology, to create major product opportunities in the health and high tech sectors. BTG has commercialised important innovations, including Magnetic Resonance Imaging, Multilevel Cell Memory, Campath (alemtuzumab), the first monoclonal antibody treatment for chronic lymphocytic leukaemia, and recombinant Factor IX blood clotting protein. BTG operates through wholly owned subsidiaries BTG International Ltd and BTG International Inc in the UK and USA, respectively. |
More News:
• For April 2007
• From BTG
• For Polymer OLED Devices
|
